Arcturus Therapeutics’ (ARCT) “Buy” Rating Reiterated at HC Wainwright

Arcturus Therapeutics (NASDAQ:ARCT)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued on Tuesday, Benzinga reports. They presently have a $60.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 153.59% from the stock’s previous close.

A number of other research firms also recently weighed in on ARCT. William Blair restated an “outperform” rating on shares of Arcturus Therapeutics in a report on Thursday, May 23rd. Canaccord Genuity Group decreased their price target on Arcturus Therapeutics from $87.00 to $86.00 and set a “buy” rating for the company in a report on Friday, May 10th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $64.86.

Arcturus Therapeutics Trading Down 2.8 %

Shares of NASDAQ:ARCT opened at $23.66 on Tuesday. The company has a fifty day moving average of $30.12 and a 200-day moving average of $32.62. Arcturus Therapeutics has a 52-week low of $17.52 and a 52-week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($1.00) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.17) by $0.17. The business had revenue of $38.01 million during the quarter, compared to the consensus estimate of $22.12 million. Arcturus Therapeutics had a negative return on equity of 37.61% and a negative net margin of 81.59%. As a group, equities research analysts predict that Arcturus Therapeutics will post -4.39 earnings per share for the current fiscal year.

Insider Transactions at Arcturus Therapeutics

In other news, COO Pad Chivukula sold 26,000 shares of the stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $40.01, for a total transaction of $1,040,260.00. Following the transaction, the chief operating officer now owns 447,448 shares of the company’s stock, valued at approximately $17,902,394.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 13.80% of the company’s stock.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ARCT. Russell Investments Group Ltd. bought a new position in Arcturus Therapeutics in the 1st quarter valued at about $40,000. AJOVista LLC bought a new position in Arcturus Therapeutics in the 4th quarter valued at about $65,000. Quest Partners LLC bought a new position in Arcturus Therapeutics in the 4th quarter valued at about $67,000. Public Employees Retirement System of Ohio bought a new position in Arcturus Therapeutics in the 4th quarter valued at about $89,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in Arcturus Therapeutics by 352.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,089 shares of the biotechnology company’s stock valued at $97,000 after acquiring an additional 2,406 shares in the last quarter. Institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.